https://www.selleckchem.com/products/cmc-na.html
6months vs. not reached, p 0.0001). Patients with relapse had significantly more monthly ED visits (mean [SD] 0.10 [0.24] vs. 0.03 [0.08], p 0.0001) and hospitalizations (mean [SD] 0.20 [0.43] vs. 0.05 [0.10], p 0.0001) following relapse than before relapse. Patients with stage II-IIIB NSCLC treated with adjuvant therapy after complete resection had high relapse rates, reduced survival, and significantly increased healthcare resource use when relapse occurred. New therapeutic options to reduce relapse rates in patients wit
Like
Comment
Share
